Literature DB >> 10609557

Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas.

P G Penketh1, K Shyam, A C Sartorelli.   

Abstract

1,2-Bis(sulfonyl)hydrazine derivatives, designed to generate several of the electrophilic species classically believed to be responsible for the alkylating (chloroethylating) and/or carbamoylating activities of the chloroethylnitrosoureas (CNUs), were compared with respect to the cross-linking and nicking of T7 DNA to that caused by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and 1-(2-chloroethyl)-3-(4-trans-methylcyclohexyl)-1-nitrosourea (MeCCNU). In the case of BCNU, a large proportion of T7 DNA strand nicking was found to be due to the generation of 2-chloroethylamine, produced from the hydrolysis of 2-chloroethylisocyanate, in turn formed during the decomposition of the parental nitrosourea. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine (compound 1) gave a greater yield of DNA cross-links than the CNUs. Compound 1, as well as its derivatives that were incapable of generating 2-chloroethylisocyanate, did not produce detectable levels of strand nicking, indicating that N7-alkylation of guanine did not occur to a significant extent with these agents. Since compound 1 and its derivatives are believed to generate chloronium and chloroethyldiazonium ions, it would appear that these species could not be significantly involved in the N7-alkylation of guanine caused by the CNUs. The relatively low level of N7-alkylation of guanine residues and the relatively high yield of cross-links generated by some of the 1,2-bis(sulfonyl)-1-(2-chloroethyl)hydrazine derivatives implies that they are more exclusive O6-guanine chloroethylating agents than the CNUs. O6-Guanine chloroethylation is believed to be the therapeutically relevant event produced by the CNUs; therefore, compound 1 derivatives represent promising new cancer chemotherapeutic agents, since they appear to generate lower quantities of therapeutically unimportant, yet carcinogenic lesions, and more of the therapeutically relevant O6-guanine chloroethylation than the CNUs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10609557     DOI: 10.1016/s0006-2952(99)00328-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  26 in total

1.  pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugs.

Authors:  Philip G Penketh; Richard A Finch; Rachel Sauro; Raymond P Baumann; Elena S Ratner; Krishnamurthy Shyam
Journal:  Chem Biol Drug Des       Date:  2017-07-17       Impact factor: 2.817

2.  1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.

Authors:  Helen A Seow; Philip G Penketh; Krishnamurthy Shyam; Sara Rockwell; Alan C Sartorelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-17       Impact factor: 11.205

3.  Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine.

Authors:  Kimiko Ishiguro; Helen A Seow; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

4.  Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.

Authors:  Sara Rockwell; Yanfeng Liu; Helen A Seow; Kimiko Ishiguro; Raymond P Baumann; Philip G Penketh; Krishnamurthy Shyam; Oluwatoyin M Akintujoye; Peter M Glazer; Alan C Sartorelli
Journal:  Int J Radiat Biol       Date:  2011-12-20       Impact factor: 2.694

5.  Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rat.

Authors:  John Mao; Yang Xu; Diana Wu; Bijan Almassain
Journal:  AAPS PharmSci       Date:  2002

6.  Reductive activation of the prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119) selectively occurs in oxygen-deficient cells and overcomes O(6)-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance.

Authors:  Raymond P Baumann; Philip G Penketh; Kimiko Ishiguro; Krishnamurthy Shyam; Yong L Zhu; Alan C Sartorelli
Journal:  Biochem Pharmacol       Date:  2009-12-11       Impact factor: 5.858

7.  Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O(6)-benzylguanine to the protein.

Authors:  Kimiko Ishiguro; Krishnamurthy Shyam; Philip G Penketh; Alan C Sartorelli
Journal:  Anal Biochem       Date:  2008-08-20       Impact factor: 3.365

8.  Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.

Authors:  G Krishna; W F Hodnick; W Lang; X Lin; S Karra; J Mao; B Almassian
Journal:  AAPS PharmSciTech       Date:  2001-08-26       Impact factor: 3.246

9.  When alcohol is the answer: Trapping, identifying and quantifying simple alkylating species in aqueous environments.

Authors:  Philip G Penketh; Krishnamurthy Shyam; Raymond P Baumann; Rui Zhu; Kimiko Ishiguro; Alan C Sartorelli; Elena S Ratner
Journal:  Anal Biochem       Date:  2016-05-14       Impact factor: 3.365

10.  Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species.

Authors:  Philip G Penketh; Raymond P Baumann; Kimiko Ishiguro; Krishnamurthy Shyam; Helen A Seow; Alan C Sartorelli
Journal:  Leuk Res       Date:  2008-05-13       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.